I-BET151

News alerts, weekly reports and conference planners

Company:

GSK

Drug class:

BRD4 inhibitor, BRD2 inhibitor, BRD3 inhibitor

Related drugs:

KMT2A rearrangement	Acute Myelogenous Leukemia	KMT2A rearrangement	Acute Myelogenous Leukemia	venetoclax + sunitinib + I-BET151 Sensitive: C3 – Early Trials venetoclax + sunitinib + I-BET151 Sensitive : C3	venetoclax + sunitinib + I-BET151 Sensitive: C3 – Early Trials venetoclax + sunitinib + I-BET151 Sensitive : C3
MYCL overexpression	Multiple Myeloma	MYCL overexpression	Multiple Myeloma	I-BET151 Sensitive: D – Preclinical I-BET151 Sensitive : D	I-BET151 Sensitive: D – Preclinical I-BET151 Sensitive : D

Associations
(2)